Literature DB >> 11801310

Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.

Roelandt F J Schop1, Syed M Jalal, Scott A Van Wier, Gregory J Ahmann, Richard J Bailey, Robert A Kyle, Philip R Greipp, S Vincent Rajkumar, Morie A Gertz, John A Lust, Martha Q Lacy, Angela Dispenzieri, Thomas E Witzig, Rafael Fonseca.   

Abstract

Waldenström macroglobulinemia (WM) is a plasma cell dyscrasia characterized by a monoclonal IgM paraproteinemia. Deletions of 17p13.1 and 13q14 are associated with tumor progression and worsened outcome in multiple myeloma (MM), and we thus investigated WM patients for their presence. Patients (n = 40) were required to have a > or = 1.5 g/dl serum IgM paraproteinemia and a monoclonal lymphoplasmacytic infiltrate. We used interphase fluorescence in situ hybridization (FISH) with probes that localized to 17p13.1(LSI p53/CEP 17) and 13q14 (D13S319 and LSI 13 Rb). Of 40 successfully studied patients for 17p13.1(p53) deletions, 6 were abnormal, consistent with hemizygous deletion (15%). Of 37 cases successfully studied for the 13q14 deletions, 6 were also abnormal with one pair of signals deleted (16%). Patients with deletions were more likely to be later in the course of the disease. No obvious clinical associations were noted with the exception that patients with 17p13.1(p53) deletions had a higher percent involvement of clonal cells in the bone marrow. Deletions of these two regions are uncommon in WM, being more common in the late stages of the disease, thus unlikely playing a role in primary disease pathogenesis.

Entities:  

Mesh:

Year:  2002        PMID: 11801310     DOI: 10.1016/s0165-4608(01)00526-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

Review 1.  Targeting the bone marrow in Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Yong Zhang; Yang Liu; Hai Ngo; Feda Azab; Antonio Sacco; Abdelkareem Azab; Patricia Maiso; Brittany Morgan; Phong Quang; Ghayas C Issa; Xavier Leleu; Aldo M Roccaro
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-30

2.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Authors:  Florence Nguyen-Khac; Jerome Lambert; Elise Chapiro; Aurore Grelier; Sarah Mould; Carole Barin; Agnes Daudignon; Nathalie Gachard; Stéphanie Struski; Catherine Henry; Dominique Penther; Hossein Mossafa; Joris Andrieux; Virginie Eclache; Chrystèle Bilhou-Nabera; Isabelle Luquet; Christine Terre; Laurence Baranger; Francine Mugneret; Jean Chiesa; Marie-Joelle Mozziconacci; Evelyne Callet-Bauchu; Lauren Veronese; Hélène Blons; Roger Owen; Julie Lejeune; Sylvie Chevret; Hélène Merle-Beral; Véronique Leblondon
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

3.  Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor H Jimenez-Zepeda; Riccardo Valdez; Roelandt F J Schop; Tammy Price-Troska; Kimberly Henderson; Antonio Sacco; Feda Azab; Philip Greipp; Morie Gertz; Suzanne Hayman; S Vincent Rajkumar; John Carpten; Marta Chesi; Michael Barrett; A Keith Stewart; Ahmet Dogan; P Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

4.  High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

Authors:  Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor Hugo Jimenez-Zepeda; Roelandt F J Schop; Marta Chesi; Michael Barrett; Alexander Keith Stewart; Ahmet Dogan; Peter Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

Review 5.  Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.

Authors:  Natalia Neparidze; Madhav V Dhodapkar
Journal:  Clin Adv Hematol Oncol       Date:  2009-10

6.  TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authors:  Moshe E Gatt; Kohichi Takada; Mala Mani; Mikael Lerner; Marjorie Pick; Teru Hideshima; Daniel E Carrasco; Alexei Protopopov; Elena Ivanova; Olle Sangfelt; Dan Grandér; Bart Barlogie; John D Shaughnessy; Kenneth C Anderson; Daniel R Carrasco
Journal:  Br J Haematol       Date:  2013-05-07       Impact factor: 6.998

7.  MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts.

Authors:  L S Hodge; S F Elsawa; D M Grote; T L Price-Troska; Y W Asmann; R Fonseca; M A Gertz; T E Witzig; A J Novak; S M Ansell
Journal:  Blood Cancer J       Date:  2011-06-17       Impact factor: 11.037

8.  Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Authors:  Shuhua Yi; Zengjun Li; Dehui Zou; Wenjie Xiong; Heng Li; Rui Cui; Chengwen Li; Yuting Yan; Wei Liu; Rui Lv; Zhen Yu; Weiwei Chen; Yan Xu; Gang An; Huijun Wang; Kun Ru; Tao Cheng; Jianxiang Wang; Lugui Qiu
Journal:  Oncotarget       Date:  2017-12-15

9.  Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.

Authors:  S M Ansell; L S Hodge; F J Secreto; M Manske; E Braggio; T Price-Troska; S Ziesmer; Y Li; S H Johnson; S N Hart; J-P A Kocher; G Vasmatzis; A Chanan-Kahn; M Gertz; R Fonseca; A Dogan; J R Cerhan; A J Novak
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037

10.  Candidate genes of Waldenström's macroglobulinemia: current evidence and research.

Authors:  Giada Bianchi; Antonio Sacco; Shaji Kumar; Giuseppe Rossi; Irene Ghobrial; Aldo Roccaro
Journal:  Appl Clin Genet       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.